ESMO 2022 - Results from #60

Viewing 61-80 of 82 articles

ESMO 2022: Alkaline Phosphatase Decline and Pain Response as Markers for OS in Patients with mCRPC Treated with Radium-223 in the REASSURE Study

ESMO 2022: Additional Insights from the STAMPEDE Trial Platform

ESMO 2022: Effect of Abiraterone-Prednisone in mCSPC with Neuroendocrine and Very High-Risk Features in the PEACE-1 Trial

ESMO 2022: Quality of Life Across Three Countries Using a Large-Scale, Fully Digital Survey of Patients With Prostate Cancer

ESMO 2022: CYCLONE 3: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-risk mHSPC

ESMO 2022: Comparison of Abiraterone Acetate and Prednisolone or Combination Enzalutamide + Abiraterone Acetate and Prednisolone for mHSPC Starting ADT: OS Results of 2 Randomized Phase III Trials from the STAMPEDE Protocol

ESMO 2022: Discussion of PRESTO in High-Risk Biochemically Relapsed Prostate Cancer and PROpel in mCRPC

ESMO 2022: Biomarker Analysis and Updated Results from the Phase III PROpel Trial of Abiraterone and Olaparib vs Abiraterone and Placebo as First-Line Therapy for Patients with mCRPC

ESMO 2022: A Phase 1b Study of a Single Priming Dose of 177Lu-PSMA-617 Coupled with Pembrolizumab in Metastatic Castration Resistant Prostate Cancer

ESMO 2022: PRESTO: A Phase 3, Open-Label Study of Androgen Annihilation in Patients with High-Risk Biochemically Relapsed Prostate Cancer (AFT-19)

ESMO 2022: Clinical Qualification of Transcriptome Signatures for Advanced Prostate Cancer Starting ADT with or Without Abiraterone Acetate and Prednisolone: An Ancillary Study of the STAMPEDE AAP Trial

ESMO 2022: Do the Results of the Perioperative Renal Cancer Trials Make Any Sense?

ESMO 2022: IMmotion010: Efficacy and Safety from the Phase III Study of Atezolizumab vs Placebo as Adjuvant Therapy in Patients with RCC at Increased Risk of Recurrence After Resection

ESMO 2022: Phase III RandOmized Study Comparing PErioperative Nivolumab versus Observation in Patients with RCC Undergoing Nephrectomy (PROSPER, ECOG-ACRIN EA8143), a National Clinical Trials Network Trial

ESMO 2022: PD-L1 Expression on Immune Cells by SP142 Co-Localizes with Dendritic Cells and Is Associated with Improved OS with Atezolizumab in Patients with Untreated Metastatic Urothelial Cancer

ESMO 2022: Biomarkers for Advanced Urothelial Carcinoma: Are We There Yet?

ESMO 2022: Genomic Biomarkers in Peripheral Blood From Patients Enrolled in the JAVELIN Bladder 100 Trial of Avelumab First-line Maintenance in Advanced Urothelial Carcinoma

Great Oaks Grow from Small Acorns: Oncology Is Committed to Doing Its Part for Sustainability

Exelixis Announces Detailed Results from Phase 3 COSMIC-313 Pivotal Trial in Patients with Previously Untreated Advanced Kidney Cancer at ESMO 2022

Merck to Present New Data at ESMO 2022 Congress From Its Broad Oncology Portfolio and Promising Pipeline, Demonstrating Commitment to Improving Long-Term Survival in Multiple Types of Cancer

1
2
3
4
5